therivabio.com - TOVX Total Company Value

Graphic logo of Theriva Corp (TOVX)

Theriva Biologics, Inc. (TOVX) minimizes risks by developing microbiome protection agents and antiviral oncology drugs. The company implements AI models and bioreactor automation to eliminate human error during production. High standing within the scientific community confirms the reliability of its clinical profile. The share price visualized below on GURU.Markets is 0.03, reflecting the current market valuation of the business.

Theriva Biologics, Inc. (TOVX) - Total Company Value from 11/23/2025 to 11/01/2026

Theriva Biologics, Inc. (TOVX) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price Theriva Biologics Inc|TOVX - Consensus Target
- issuer market value details:
Market Value Theriva Biologics|TOVX - Real Price to Acquire Entire Company
- business book valuation details:
Equity per Share Theriva Biologics|TOVX - Company Book Value|Market-to-Book Ratio therivabio.com|TOVX - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Ratio Theriva Biologics, Inc.|TOVX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio therivabio.com|TOVX - Company Debts|Debts to Book Value Theriva Biologics|TOVX - Company Long-Term Debt|Company Short-Term Debt Theriva Biologics|Immediate Liquidity therivabio.com
- earnings and valuation multiples indicators:
TOVX - Net Profit
Analysis of all company metrics:Theriva Biologics, Inc.
Flagship merchandise of Theriva Biologics

Enterprise value combines market capitalization with net debt, determining the actual price for a full buyout of the business minus liquid assets. When analyzing the enterprise value of Theriva Biologics, Inc. (TOVX), an investor must weigh it against the high risks of oncolytic virus clinical trials, as any development failure could instantaneously wipe out the capital investments embedded in this metric.

Competitors of Theriva Biologics, Inc. (TOVX)

ImmunityBio Inc (IBRX) - Total Enterprise Value|IMCR: Real Price to Acquire Entire Company|JANX: Total Company Value|RCUS (Arcus Biosciences, Inc.) - Real Price to Acquire Entire Company|Business Value ZYME|Total Company Value Tango Therapeutics, Inc.|Total Enterprise Value Iovance Biotherapeutics Inc IOVA|Total Company Value Immatics Corp (IMTX)|Xencor Inc. - Business Value|Enterprise Value CMPX (Compass Therapeutics)|REPL - Real Price to Acquire Entire Company|LYEL - Total Company Value|Total Enterprise Value Innate Pharma SA|pyxisoncology.com (PYXS) - Total Company Value|CGEN (Compugen) - Total Company Value|Total Company Value IO Biotech, Inc.|Total Enterprise Value sutrobio.com STRO|Enterprise Value INKT|werewolftx.com (HOWL) - Full Takeover Company Value|Immix Biopharma - Real Price to Acquire Entire Company|ALX Oncology Holdings Inc. (ALXO) - Total Enterprise Value|CUE: Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash PDSB (PDS Biotechnology)|SONN: Enterprise Value|MAIA - Company Buyout Price|Total Company Value Liminatus Pharma Corp|Real Price to Acquire Entire Company Lava Tx (LVTX)|Total Company Value NextCure, Inc. (NXTC)|Real Price to Acquire Entire Company leaptx.com LPTX|Intensity Therapeutics, Inc. - Real Price to Acquire Entire Company|Enterprise Value Sensei Biotherapeutics Inc SNSE|GRTS - Total Company Value|KA (Kineta Corp) - Business Value|NexImmune, Inc. (NEXI) - Total Company Value|Total Enterprise Value Turnstone Biologics Corp. (TSBX)|Real Price to Acquire Entire Company VCNX|HARP - Full Takeover Company Value